Altimmune Earnings Calls

Sep 30, 2025
-$0.210 (27.59%)
Release date Nov 06, 2025
EPS estimate -$0.290
EPS actual -$0.210
EPS Surprise 27.59%
Revenue estimate 560
Revenue actual 5K
Revenue Surprise 792.86%
Jun 30, 2025
-$0.270 (15.63%)
Release date Aug 12, 2025
EPS estimate -$0.320
EPS actual -$0.270
EPS Surprise 15.63%
Revenue estimate 1.429K
Revenue actual 5K
Revenue Surprise 249.90%
Mar 31, 2025
-$0.260 (25.71%)
Release date May 13, 2025
EPS estimate -$0.350
EPS actual -$0.260
EPS Surprise 25.71%
Revenue estimate 560
Revenue actual 5K
Revenue Surprise 792.86%
Dec 31, 2024
-$0.330 (2.94%)
Release date Feb 27, 2025
EPS estimate -$0.340
EPS actual -$0.330
EPS Surprise 2.94%
Revenue estimate 1000
Revenue actual 5K
Revenue Surprise 400.00%

Last 4 Quarters for Altimmune

Below you can see how ALT performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.

SIGN UP FREE
or
Creating an account or logging in means you agree to StockInvest.us Terms of Use and Privacy Policy.
Dec 31, 2024 Beat
Release date Feb 27, 2025
Price on release $6.42
EPS estimate -$0.340
EPS actual -$0.330
EPS surprise 2.94%
Date Price
Feb 21, 2025 $6.43
Feb 24, 2025 $6.11
Feb 25, 2025 $5.91
Feb 26, 2025 $5.94
Feb 27, 2025 $6.42
Feb 28, 2025 $6.65
Mar 03, 2025 $5.99
Mar 04, 2025 $5.96
Mar 05, 2025 $5.72
4 days before -0.156%
4 days after -10.90%
On release day 3.58%
Change in period -11.04%
Mar 31, 2025 Beat
Release date May 13, 2025
Price on release $5.76
EPS estimate -$0.350
EPS actual -$0.260
EPS surprise 25.71%
Date Price
May 07, 2025 $5.36
May 08, 2025 $5.80
May 09, 2025 $5.59
May 12, 2025 $6.01
May 13, 2025 $5.76
May 14, 2025 $5.70
May 15, 2025 $5.78
May 16, 2025 $5.58
May 19, 2025 $5.50
4 days before 7.46%
4 days after -4.51%
On release day -1.04%
Change in period 2.61%
Jun 30, 2025 Beat
Release date Aug 12, 2025
Price on release $3.62
EPS estimate -$0.320
EPS actual -$0.270
EPS surprise 15.63%
Date Price
Aug 06, 2025 $3.60
Aug 07, 2025 $3.52
Aug 08, 2025 $3.45
Aug 11, 2025 $3.38
Aug 12, 2025 $3.62
Aug 13, 2025 $3.74
Aug 14, 2025 $3.68
Aug 15, 2025 $3.63
Aug 18, 2025 $3.56
4 days before 0.556%
4 days after -1.66%
On release day 3.31%
Change in period -1.11%
Sep 30, 2025 Beat
Release date Nov 06, 2025
Price on release $3.94
EPS estimate -$0.290
EPS actual -$0.210
EPS surprise 27.59%
Date Price
Oct 31, 2025 $4.05
Nov 03, 2025 $3.96
Nov 04, 2025 $3.76
Nov 05, 2025 $3.75
Nov 06, 2025 $3.94
Nov 07, 2025 $4.11
Nov 10, 2025 $4.26
Nov 11, 2025 $4.28
Nov 12, 2025 $4.23
4 days before -2.72%
4 days after 7.36%
On release day 4.31%
Change in period 4.44%

Altimmune Earnings History

Earnings Calendar

FAQ

When is the earnings report for ALT?
Altimmune, Inc. (ALT) has scheduled its earnings report for Feb 26, 2026 before the markets open.

What is the ALT price-to-earnings (P/E) ratio?
ALT P/E ratio as of Nov 17, 2025 (TTM) is -4.33.

What is the ALT EPS forecast?
The forecasted EPS (Earnings Per Share) for Altimmune, Inc. (ALT) for the first fiscal quarter 2025 is -$0.250.

What are Altimmune, Inc.'s retained earnings?
On its balance sheet, Altimmune, Inc. reported retained earnings of $5.00 thousand for the latest quarter ending Sep 30, 2025.

What Is an Earnings Report?
An earnings report is usually issued quarterly (Q1, Q2, Q3 & Q4) by public companies to report their performance. Earnings reports typically include net income, earnings per share, earnings from continuing operations, and net sales. Looking at the earnings report investors can start gauge the financial health of the company and make even better decisions whether to buy, sell, or stay in the company. Fundamental analysts and value investors will typically hunt for stocks that continue to show good financial ratios and use a decline as an exit point. One of the most anticipated numbers for analysis is earnings per share because it indicates how much the company earned for its shareholders. The report will also indicate a possible dividend.

Earnings Report Content
Earnings reports generally provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. These figures are typically measured against previous quarters/years. Furthermore, the earnings report usually includes a summary and analysis from the CEO or company spokesman, alongside a more general view of the financials and future forecast.

What To Know About Earnings Reports?
Announcement of earnings for a stock, particularly for well followed large-capitalization stocks, can move the market. Stock prices can fluctuate wildly on days when the quarterly earnings report is released. Despite good reports, stocks may very well fall if the investors were expecting more or they believe the next quarter will not be as good. Investors always try to be ahead of the market and future earnings/losses are often discounted into the current price of the stock. It is natural for stocks to start to move in either direction a few days before the release of an earnings report.
Click to get the best stock tips daily for free!
ABOUT ALTIMMUNE, INC.
Altimmune
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinica...
GOLDEN STAR
Ticker Change Signal Date
UNIT
$6.00
4.83% Nov 04
TBPH
$14.14
27.58% Oct 23
A
AMIX
$1.12
2.68% Oct 23
COCO
$40.85
11.21% Oct 23
LAUR
$29.55
1.20% Oct 22

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE